Fidelity Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$119M Buy
596,127
+16,972
+3% +$3.36M 0.01% 1099
2025
Q4
$110M Buy
579,155
+121,924
+27% +$23.4M 0.01% 1134
2025
Q3
$81M Buy
457,231
+431,008
+1,644% +$64.1M ﹤0.01% 1267
2025
Q2
$2.98M Buy
26,223
+1,290
+5% +$138K ﹤0.01% 2348
2025
Q1
$2.62M Buy
24,933
+6,102
+32% +$690K ﹤0.01% 2358
2024
Q4
$2.02M Buy
18,831
+6,082
+48% +$688K ﹤0.01% 2444
2024
Q3
$1.28M Buy
12,749
+10,789
+550% +$1.09M ﹤0.01% 2532
2024
Q2
$165K Buy
1,960
+152
+8% +$12.1K ﹤0.01% 3099
2024
Q1
$132K Sell
1,808
-8,185
-82% -$603K ﹤0.01% 3177
2023
Q4
$714K Buy
9,993
+9,655
+2,857% +$570K ﹤0.01% 2569
2023
Q3
$20.3K Sell
338
-221
-40% -$14.5K ﹤0.01% 3794
2023
Q2
$40.3K Sell
559
-7
-1% -$525 ﹤0.01% 3539
2023
Q1
$41.6K Buy
566
+156
+38% +$11.1K ﹤0.01% 3528
2022
Q4
$27.4K Sell
410
-885
-68% -$57.5K ﹤0.01% 3659
2022
Q3
$70K Buy
1,295
+51
+4% +$3K ﹤0.01% 3363
2022
Q2
$69K Sell
1,244
-686
-36% -$38.9K ﹤0.01% 3449
2022
Q1
$135K Buy
1,930
+1,258
+187% +$91.3K ﹤0.01% 3356
2021
Q4
$64K Sell
672
-6
-0.9% -$554 ﹤0.01% 3178
2021
Q3
$59K Sell
678
-1,125
-62% -$87K ﹤0.01% 3176
2021
Q2
$148K Buy
1,803
+24
+1% +$2K ﹤0.01% 2975
2021
Q1
$169K Buy
1,779
+330
+23% +$31.2K ﹤0.01% 2847
2020
Q4
$90K Sell
1,449
-335
-19% -$19.1K ﹤0.01% 2897
2020
Q3
$107K Sell
1,784
-4,984
-74% -$340K ﹤0.01% 2782
2020
Q2
$472K Sell
6,768
-11,594
-63% -$735K ﹤0.01% 2517
2020
Q1
$832K Sell
18,362
-73,192
-80% -$4.15M ﹤0.01% 2359
2019
Q4
$5.96M Sell
91,554
-13,652
-13% -$912K ﹤0.01% 2007
2019
Q3
$6.53M Sell
105,206
-98,859
-48% -$6.21M ﹤0.01% 1968
2019
Q2
$14.5M Sell
204,065
-243,982
-54% -$18M ﹤0.01% 1750
2019
Q1
$35.1M Sell
448,047
-95,280
-18% -$7.22M ﹤0.01% 1367
2018
Q4
$46M Sell
543,327
-316,894
-37% -$33.8M 0.01% 1178
2018
Q3
$147M Buy
860,221
+153,965
+22% +$23.2M 0.02% 784
2018
Q2
$91.3M Buy
706,256
+22,469
+3% +$2.51M 0.01% 999
2018
Q1
$70.5M Sell
683,787
-5,317
-0.8% -$526K 0.01% 1138
2017
Q4
$58.9M Sell
689,104
-163,828
-19% -$14.2M 0.01% 1220
2017
Q3
$72.4M Buy
852,932
+209,788
+33% +$16.6M 0.01% 1125
2017
Q2
$48.7M Sell
643,144
-36,629
-5% -$2.56M 0.01% 1292
2017
Q1
$44.9M Sell
679,773
-99,386
-13% -$6.54M 0.01% 1359
2016
Q4
$49.4M Sell
779,159
-759,822
-49% -$47.9M 0.01% 1302
2016
Q3
$98M Sell
1,538,981
-152,926
-9% -$11.2M 0.01% 987
2016
Q2
$126M Buy
1,691,907
+128,560
+8% +$9.54M 0.02% 870
2016
Q1
$104M Sell
1,563,347
-216,885
-12% -$13.2M 0.01% 945
2015
Q4
$120M Buy
1,780,232
+113,333
+7% +$7M 0.02% 882
2015
Q3
$89.1M Buy
1,666,899
+33,070
+2% +$2.01M 0.01% 1001
2015
Q2
$103M Buy
1,633,829
+6,316
+0.4% +$345K 0.01% 1029
2015
Q1
$78.3M Buy
1,627,513
+105,195
+7% +$4.03M 0.01% 1141
2014
Q4
$50.5M Sell
1,522,318
-744,273
-33% -$24.2M 0.01% 1322
2014
Q3
$66.4M Sell
2,266,591
-488,142
-18% -$16.2M 0.01% 1170
2014
Q2
$107M Buy
2,754,733
+86,081
+3% +$3.49M 0.01% 963
2014
Q1
$112M Hold
2,668,652
0.02% 926
2013
Q4
$87.6M Hold
2,668,652
0.01% 1046
2013
Q3
$72.1M Buy
2,668,652
+711,251
+36% +$20M 0.01% 1103
2013
Q2
$45.7M Buy
+1,957,401
New +$35.2M 0.01% 1284

Other funds holding LGND

Fidelity Investments's LGND Position: Q1 2026 in Review

Fidelity Investments increased its Ligand Pharmaceuticals (LGND) stake by 2.9% in Q1 2026, buying an estimated $3.36M and bringing the position to 596,127 shares worth $119M. The position accounts for 0.01% of the portfolio, ranked #1099.

Fidelity Investments first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $147M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Fidelity Investments held 596,127 shares of Ligand Pharmaceuticals worth $119M as of Q1 2026.
  • Fidelity Investments bought 16,972 Ligand Pharmaceuticals shares in Q1 2026, an estimated $3.36M.
  • Ligand Pharmaceuticals made up 0.01% of Fidelity Investments's portfolio in Q1 2026, its #1099 holding.
  • Fidelity Investments first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Fidelity Investments's Ligand Pharmaceuticals position peaked at $147M in Q3 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.